৳ 195,000/unit
Pack: ৳ 195,000
৳ 195,000/unit
Pack: ৳ 195,000
At a glance
Pembrolizumab is a programmed death receptor-1 (PD-1)-blocking antibody used for the treatment of melanoma, non-small cell lung cancer, head and neck cancer, cervical cancer, and various other cancers.
Indications
- Melanoma (unresectable or metastatic)
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
- Head and Neck Squamous Cell Cancer (HNSCC)
- Classical Hodgkin Lymphoma (cHL)
- Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- Urothelial Carcinoma
- Microsatellite Instability-High (MSI-H) Cancer
- Gastric Cancer
- Esophageal Cancer
- Cervical Cancer
- Hepatocellular Carcinoma (HCC)
- Merkel Cell Carcinoma (MCC)
- Renal Cell Carcinoma (RCC)
- Endometrial Carcinoma
Pharmacology
Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
Dosage
Adult Dose (Intravenous):
- Most indications: 200 mg once every 3 weeks as 30-minute IV infusion
- Pediatric (cHL, PMBCL, MSI-H, MCC): 2 mg/kg (up to 200 mg) every 3 weeks
- RCC: With axitinib 5 mg orally twice daily
- Endometrial Carcinoma: With lenvatinib 20 mg orally once daily (not MSI-H or dMMR)
- Until disease progression or unacceptable toxicity, or up to 24 months (35 cycles) without disease progression
Side effects
Common Side Effects (≥20%):
- Fatigue
- Musculoskeletal pain
- Decreased appetite
- Pruritus
- Diarrhea
- Nausea
- Rash
- Pyrexia
- Cough
- Dyspnea
- Constipation
- Abdominal pain
Use in pregnancy
Use in Pregnancy: Can cause fetal harm when administered to a pregnant woman; advise women of potential risk to the fetus.
Pregnancy Category: D — always consult a doctor before taking during pregnancy.
Precautions & warnings
- Immune-mediated pneumonitis, colitis, hepatitis, nephritis, endocrinopathies, skin reactions: Withhold or permanently discontinue based on severity
- Infusion-related reactions: Discontinue for severe/life-threatening reactions
- Complications of allogeneic HSCT: Monitor for GVHD, hepatic veno-occlusive disease
- Treatment of multiple myeloma with PD-1/PD-L1 blocker + thalidomide analogue + dexamethasone not recommended outside controlled trials
- Embryo-fetal toxicity: Potential risk to fetus; use effective contraception
Overdose effects
No overdose information available; treatment: general supportive measures.
Storage conditions
Store at 2-8°C in the refrigerator; after reconstitution, use within 24 hours.